贝伐单抗：一种新的经营方式？
Bevacizumab: a new way of doing business?
作者信息
Canning C, Lotery A
机构信息
Southampton Eye Unit, Southampton General Hospital, Southampton, UK.
出版信息
Eye (Lond). 2006 Sep;20(9):985-7. doi: 10.1038/sj.eye.6702501. Epub 2006 Jul 21.
This review highlights the history of the development of treatments for choroidal neovascularization (wct AMD). It examines how drug therapies have evolved for the management of age-related macular degeneration (AMD) and the value of randomised clinical trials in determining efficacy. Finally it examines the emerging practice of utilising bevacizumab for the treatment of choroidal neovascularization despite the lack of any phase III clinical trial data.
本综述重点介绍了脉络膜新生血管（湿性年龄相关性黄斑变性）治疗方法的发展历程。它探讨了药物疗法在年龄相关性黄斑变性（AMD）管理方面的演变，以及随机临床试验在确定疗效方面的价值。最后，它审视了尽管缺乏任何III期临床试验数据，但利用贝伐单抗治疗脉络膜新生血管这一新兴做法。
Zotero 插件